Advertiser Disclosure: We may earn commissions from partner links at no cost to you. This never affects our editorial content or recommendations.

Healthcare AI NYSE: NVO

Novo Nordisk A/S (NVO)

The original GLP-1 innovator navigating competition from Lilly while building next-generation obesity drugs.

— loading… 15-min delay · Not financial advice
✓ Reviewed by Get AI Decoded Editorial Team Updated April 2026
← All Healthcare AI Stocks

Sponsored Placement Available

Sponsor this NVO page — reach investors tracking NVO

View Options →

The AI Angle

Novo Nordisk invented the GLP-1 drug category and built two blockbuster franchises: Ozempic (semaglutide, diabetes) and Wegovy (semaglutide, obesity). Combined, these drugs generated approximately $33 billion in annualized revenue as of mid-2025. However, 2025 was a year of recalibration: Novo lowered its full-year guidance four times as US market growth slowed, Lilly's tirzepatide gained share, and compounded semaglutide from telehealth players ate into branded prescriptions. Full-year 2025 sales reached approximately $46.8 billion, up ~11% year-over-year.

The forward battleground is next-generation obesity treatments. Novo's CagriSema (cagrilintide + semaglutide combination) is in late-stage trials targeting 25%+ weight loss — competitive with Lilly's retatrutide. Novo is also investing in AI for drug discovery through its Oxford-based research collaborations and has announced plans to slash US GLP-1 list prices by up to 70% to compete with compounders and expand market access. The obesity drug market is projected to reach $130+ billion by 2030, and Novo remains one of two companies at the frontier.

Key Numbers

~$46.8B
2025 Full Year Revenue
+11% YoY in USD (MacroTrends)
+10%
2025 Sales Growth at CER
Constant exchange rate; in-line with lowered guidance
~$14.8B combined
Ozempic + Wegovy H1 2025
Ozempic ~$9.4B, Wegovy ~$5.4B (Drug Discovery Trends)
3/5
AI Exposure Score
Significant AI exposure.
⚡⚡⚡⚡⚡
⚡ About AI Exposure Score: Reflects how central AI is to this company's current revenue and growth strategy. 5 = AI is the core business. 1 = AI is a minor angle. Editorial assessment — not a buy/sell signal.

Get NVO coverage in your inbox

We cover NVO and 24 other AI stocks every morning. Free daily newsletter.

Upcoming Catalysts

  • CagriSema Phase 3 data — 25%+ weight loss potential, superior to current semaglutide
  • US GLP-1 price cuts (up to 70%) to regain volume from compounders
  • Oral semaglutide (Rybelsus) ramp and next-gen oral formulations
  • International Wegovy launch expanding into Europe, Canada, and Asia

Key Risks

  • Lilly's tirzepatide gaining share — superior efficacy narrative pressuring Wegovy
  • Slowing US demand growth: telehealth compounders providing cheaper alternatives
  • FDA scrutiny of compounded semaglutide may not materially benefit branded drugs
  • Patent expiry: Ozempic and Wegovy face generics by early 2030s

Sources: CNBC (Feb 3, 2026), Novo Nordisk Annual Report 2025, MacroTrends, Drug Discovery Trends (Nov 2025)

⚠️ Not financial advice. This page is for informational purposes only. All figures are sourced from public earnings reports, company guidance, and financial news. Past performance is not indicative of future results. Always do your own research before making any investment decisions.

Trade NVO with a top broker

Open a brokerage account to start trading. We may earn a commission if you use these links — see our disclosure.

R
Robinhood
Commission-free. No minimums.
Open Account →
T
Tastytrade
Built for active traders & options.
Open Account →
W
Webull
Advanced charts. Extended hours.
Open Account →